UBS Group Reports No Reviva Pharma Share Ownership

UBS Group AG, together with its wholly owned subsidiaries UBS Financial Services Inc. and UBS Securities LLC, reports that it no longer beneficially owns any shares of Reviva Pharmaceuticals Holdings, Inc. common stock, par value $0.0001 per share.

Rhea-AI Filing Summary

UBS Group AG, together with its wholly owned subsidiaries UBS Financial Services Inc. and UBS Securities LLC, reports that it no longer beneficially owns any shares of Reviva Pharmaceuticals Holdings, Inc. common stock, par value $0.0001 per share.

As of 06/30/2026, UBS Group discloses 0 shares beneficially owned, representing 0% of the class. It reports no sole or shared voting power and no sole or shared dispositive power over Reviva common stock, and indicates that it now holds 5 percent or less of the class.

Key Figures

Beneficial ownership shares: 0 shares Percent of class: 0% Ownership date: 06/30/2026

3 metrics

Beneficial ownership shares 0 shares Amount beneficially owned in Reviva common stock

Percent of class 0% Reported percentage of Reviva common stock class

Ownership date 06/30/2026 Date associated with reported ownership status

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, percent of class, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 0"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"Percent of class: 0 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

parent holding company regulatory

"If a parent holding company has filed this schedule"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership in RVPH does UBS Group report in this Schedule 13G/A?

UBS Group reports 0 shares of Reviva Pharmaceuticals Holdings, Inc. common stock beneficially owned, representing 0% of the class, with no sole or shared voting or dispositive power as of 06/30/2026.

Is UBS Group still a 5% beneficial owner of RVPH stock?

No. UBS Group states its beneficial ownership of Reviva Pharmaceuticals Holdings, Inc. common stock is 0%, and it confirms ownership of 5 percent or less of the class in this filing.

Which UBS entities are covered in this RVPH ownership report?

The statement is filed by UBS Group AG on behalf of itself and wholly owned subsidiaries UBS Financial Services Inc. and UBS Securities LLC, reflecting their combined beneficial ownership position in RVPH.

What voting power over RVPH shares does UBS Group report?

UBS Group reports 0 shares with sole voting power and 0 shares with shared voting power for Reviva Pharmaceuticals Holdings, Inc., indicating no voting authority over any RVPH common stock.

What dispositive power over RVPH shares does UBS Group have now?

UBS Group reports 0 shares with sole dispositive power and 0 shares with shared dispositive power in Reviva Pharmaceuticals Holdings, Inc., showing no authority to dispose of any RVPH common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:46 PM Accepted by SEC EDGAR 07/31/2026 - 04:46 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

76152G209

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 76152G209

1

Names of Reporting Persons

UBS Group AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

BK

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REVIVA PHARMACEUTICALS HOLDINGS, INC.
(b)	Address of issuer's principal executive offices: 10080 N WOLFE ROAD, 10080 N WOLFE ROAD, CUPERTINO, CALIFORNIA, 95014.
Item 2.
(a)	Name of person filing: UBS Group AG
(b)	Address or principal business office or, if none, residence: Bahnhofstrasse 45 PO Box CH-8021, Zurich, Switzerland
(c)	Citizenship: Switzerland
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 76152G209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by UBS Group AG on behalf of itself and its wholly owned subsidiaries UBS Financial Services Inc. and UBS Securities LLC.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

UBS Group AG

Signature:	Andrew Johnson
Name/Title:	Director
Date:	07/31/2026

Signature:	Anjali Tiwari
Name/Title:	Associate Director
Date:	07/31/2026